Financhill
Sell
7

APDN Quote, Financials, Valuation and Earnings

Last price:
$5.02
Seasonality move :
14.88%
Day range:
$4.51 - $4.78
52-week range:
$4.37 - $2,655.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.06x
P/B ratio:
0.23x
Volume:
61.7K
Avg. volume:
98.6K
1-year change:
-98.82%
Market cap:
$2.4M
Revenue:
$3.4M
EPS (TTM):
-$537.53

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
APDN
Applied DNA Sciences
$1.2M -$45.00 27.47% -98.87% --
FONR
Fonar
-- -- -- -- --
OCX
OncoCyte
$126.8K -$0.25 180.72% -33.33% $5.42
PRPH
ProPhase Labs
$2.5M -$0.18 3.99% -50% $13.80
VCYT
Veracyte
$111M $0.20 6.44% 332.6% $40.89
XWEL
XWELL
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
APDN
Applied DNA Sciences
$4.65 -- $2.4M -- $0.00 0% 0.06x
FONR
Fonar
$14.51 -- $91.4M 11.61x $0.00 0% 0.90x
OCX
OncoCyte
$2.64 $5.42 $75.5M -- $0.00 0% 11.97x
PRPH
ProPhase Labs
$0.36 $13.80 $15.1M -- $0.00 0% 1.97x
VCYT
Veracyte
$27.93 $40.89 $2.2B 68.12x $0.00 0% 4.77x
XWEL
XWELL
$0.95 -- $5M -- $0.00 0% 0.14x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
APDN
Applied DNA Sciences
-- 4.859 -- 3.97x
FONR
Fonar
-- 1.772 -- 9.69x
OCX
OncoCyte
-- -1.645 -- 3.57x
PRPH
ProPhase Labs
22.08% -4.000 25.51% 0.84x
VCYT
Veracyte
-- 2.499 -- 4.54x
XWEL
XWELL
-- 0.412 -- 1.41x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
APDN
Applied DNA Sciences
$370.9K -$3.5M -84.02% -84.02% -352.03% -$3.4M
FONR
Fonar
$12.1M $3.7M 5.32% 5.33% 15.23% $2.5M
OCX
OncoCyte
$1.3M -$5.9M -693.81% -693.81% -310.66% -$6.2M
PRPH
ProPhase Labs
$526K -$3.7M -101.67% -144.22% -289.24% -$3.4M
VCYT
Veracyte
$79.5M $1.2M 2.85% 2.85% 1.02% $3.5M
XWEL
XWELL
$1.3M -$3.2M -153.74% -153.74% -64.9% -$4.6M

Applied DNA Sciences vs. Competitors

  • Which has Higher Returns APDN or FONR?

    Fonar has a net margin of -336% compared to Applied DNA Sciences's net margin of 9.23%. Applied DNA Sciences's return on equity of -84.02% beat Fonar's return on equity of 5.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    APDN
    Applied DNA Sciences
    37.71% -$230.25 $10.2M
    FONR
    Fonar
    44.52% $0.37 $160.3M
  • What do Analysts Say About APDN or FONR?

    Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 483833.17%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Applied DNA Sciences has higher upside potential than Fonar, analysts believe Applied DNA Sciences is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    APDN
    Applied DNA Sciences
    0 1 0
    FONR
    Fonar
    0 0 0
  • Is APDN or FONR More Risky?

    Applied DNA Sciences has a beta of 0.054, which suggesting that the stock is 94.573% less volatile than S&P 500. In comparison Fonar has a beta of 0.993, suggesting its less volatile than the S&P 500 by 0.67700000000001%.

  • Which is a Better Dividend Stock APDN or FONR?

    Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APDN or FONR?

    Applied DNA Sciences quarterly revenues are $983.4K, which are smaller than Fonar quarterly revenues of $27.2M. Applied DNA Sciences's net income of -$3.3M is lower than Fonar's net income of $2.5M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while Fonar's PE ratio is 11.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 0.90x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APDN
    Applied DNA Sciences
    0.06x -- $983.4K -$3.3M
    FONR
    Fonar
    0.90x 11.61x $27.2M $2.5M
  • Which has Higher Returns APDN or OCX?

    OncoCyte has a net margin of -336% compared to Applied DNA Sciences's net margin of -312.02%. Applied DNA Sciences's return on equity of -84.02% beat OncoCyte's return on equity of -693.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    APDN
    Applied DNA Sciences
    37.71% -$230.25 $10.2M
    OCX
    OncoCyte
    61.97% -$0.26 $10.2M
  • What do Analysts Say About APDN or OCX?

    Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 483833.17%. On the other hand OncoCyte has an analysts' consensus of $5.42 which suggests that it could grow by 105.18%. Given that Applied DNA Sciences has higher upside potential than OncoCyte, analysts believe Applied DNA Sciences is more attractive than OncoCyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    APDN
    Applied DNA Sciences
    0 1 0
    OCX
    OncoCyte
    1 2 0
  • Is APDN or OCX More Risky?

    Applied DNA Sciences has a beta of 0.054, which suggesting that the stock is 94.573% less volatile than S&P 500. In comparison OncoCyte has a beta of 0.970, suggesting its less volatile than the S&P 500 by 3.025%.

  • Which is a Better Dividend Stock APDN or OCX?

    Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APDN or OCX?

    Applied DNA Sciences quarterly revenues are $983.4K, which are smaller than OncoCyte quarterly revenues of $2.1M. Applied DNA Sciences's net income of -$3.3M is higher than OncoCyte's net income of -$6.7M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 11.97x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APDN
    Applied DNA Sciences
    0.06x -- $983.4K -$3.3M
    OCX
    OncoCyte
    11.97x -- $2.1M -$6.7M
  • Which has Higher Returns APDN or PRPH?

    ProPhase Labs has a net margin of -336% compared to Applied DNA Sciences's net margin of -209.38%. Applied DNA Sciences's return on equity of -84.02% beat ProPhase Labs's return on equity of -144.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    APDN
    Applied DNA Sciences
    37.71% -$230.25 $10.2M
    PRPH
    ProPhase Labs
    36.76% $0.11 $19.4M
  • What do Analysts Say About APDN or PRPH?

    Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 483833.17%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3701.65%. Given that Applied DNA Sciences has higher upside potential than ProPhase Labs, analysts believe Applied DNA Sciences is more attractive than ProPhase Labs.

    Company Buy Ratings Hold Ratings Sell Ratings
    APDN
    Applied DNA Sciences
    0 1 0
    PRPH
    ProPhase Labs
    0 0 0
  • Is APDN or PRPH More Risky?

    Applied DNA Sciences has a beta of 0.054, which suggesting that the stock is 94.573% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.433, suggesting its less volatile than the S&P 500 by 143.298%.

  • Which is a Better Dividend Stock APDN or PRPH?

    Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APDN or PRPH?

    Applied DNA Sciences quarterly revenues are $983.4K, which are smaller than ProPhase Labs quarterly revenues of $1.4M. Applied DNA Sciences's net income of -$3.3M is lower than ProPhase Labs's net income of $4M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 1.97x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APDN
    Applied DNA Sciences
    0.06x -- $983.4K -$3.3M
    PRPH
    ProPhase Labs
    1.97x -- $1.4M $4M
  • Which has Higher Returns APDN or VCYT?

    Veracyte has a net margin of -336% compared to Applied DNA Sciences's net margin of 6.16%. Applied DNA Sciences's return on equity of -84.02% beat Veracyte's return on equity of 2.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    APDN
    Applied DNA Sciences
    37.71% -$230.25 $10.2M
    VCYT
    Veracyte
    69.46% $0.09 $1.2B
  • What do Analysts Say About APDN or VCYT?

    Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 483833.17%. On the other hand Veracyte has an analysts' consensus of $40.89 which suggests that it could grow by 46.4%. Given that Applied DNA Sciences has higher upside potential than Veracyte, analysts believe Applied DNA Sciences is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    APDN
    Applied DNA Sciences
    0 1 0
    VCYT
    Veracyte
    7 1 1
  • Is APDN or VCYT More Risky?

    Applied DNA Sciences has a beta of 0.054, which suggesting that the stock is 94.573% less volatile than S&P 500. In comparison Veracyte has a beta of 2.093, suggesting its more volatile than the S&P 500 by 109.267%.

  • Which is a Better Dividend Stock APDN or VCYT?

    Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APDN or VCYT?

    Applied DNA Sciences quarterly revenues are $983.4K, which are smaller than Veracyte quarterly revenues of $114.5M. Applied DNA Sciences's net income of -$3.3M is lower than Veracyte's net income of $7M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while Veracyte's PE ratio is 68.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 4.77x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APDN
    Applied DNA Sciences
    0.06x -- $983.4K -$3.3M
    VCYT
    Veracyte
    4.77x 68.12x $114.5M $7M
  • Which has Higher Returns APDN or XWEL?

    XWELL has a net margin of -336% compared to Applied DNA Sciences's net margin of -67.19%. Applied DNA Sciences's return on equity of -84.02% beat XWELL's return on equity of -153.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    APDN
    Applied DNA Sciences
    37.71% -$230.25 $10.2M
    XWEL
    XWELL
    18.78% -$1.00 $3.4M
  • What do Analysts Say About APDN or XWEL?

    Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 483833.17%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 636.84%. Given that Applied DNA Sciences has higher upside potential than XWELL, analysts believe Applied DNA Sciences is more attractive than XWELL.

    Company Buy Ratings Hold Ratings Sell Ratings
    APDN
    Applied DNA Sciences
    0 1 0
    XWEL
    XWELL
    0 0 0
  • Is APDN or XWEL More Risky?

    Applied DNA Sciences has a beta of 0.054, which suggesting that the stock is 94.573% less volatile than S&P 500. In comparison XWELL has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.658%.

  • Which is a Better Dividend Stock APDN or XWEL?

    Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APDN or XWEL?

    Applied DNA Sciences quarterly revenues are $983.4K, which are smaller than XWELL quarterly revenues of $7M. Applied DNA Sciences's net income of -$3.3M is higher than XWELL's net income of -$4.7M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 0.14x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APDN
    Applied DNA Sciences
    0.06x -- $983.4K -$3.3M
    XWEL
    XWELL
    0.14x -- $7M -$4.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Ken Griffin Buy Sweetgreen Stock?
Why Did Ken Griffin Buy Sweetgreen Stock?

In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…

Where Will Planet Labs’ Stock Go Next?
Where Will Planet Labs’ Stock Go Next?

On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…

Where Will VICI Properties Be in 5 Years?
Where Will VICI Properties Be in 5 Years?

VICI Properties (NYSE:VICI) is a real estate investment trust focused…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
73
OKLO alert for Jun 12

Oklo [OKLO] is down 1.68% over the past day.

Buy
87
SMR alert for Jun 12

NuScale Power [SMR] is down 0.99% over the past day.

Buy
53
PLAY alert for Jun 12

Dave & Buster's Entertainment [PLAY] is up 0.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock